VC
Value Add VC
โšกHomePulseโšกHelpful Apps๐Ÿ“Blog
โ† Value Add PulseIPOMost exits since 2021

Q2 2026 Delivered the Most Billion-Dollar Startup Exits Since 2021

Q2 2026 produced the most billion-dollar startup exits since the 2021 boom, led by SpaceX's blockbuster IPO and its record $60 billion purchase of Cursor parent Anysphere, according to Crunchbase data. While exit counts still trail the 2021 peak, the sheer size of deals -- with Anthropic and OpenAI now filing to test the trillion-dollar mark -- is the defining feature of the reopened liquidity window.

~$2.1T
SpaceX IPO Day-1 Cap
~$75B
SpaceX Raised
$60B
Cursor/Anysphere Deal
$5.55B raised, ~$38B cap
Cerebras IPO
$1.7B raised, ~$15.6B cap
Quantinuum IPO
TC
Trace Cohen
Early-stage VC & angel ยท Founder, New York Venture Partners
June 29, 2026
2 min read
KEY TAKEAWAYS FOR VCs & FOUNDERS
1

It confirms the venture exit market has genuinely reopened after years of drought

2

Mega-exits are the liquidity LPs need to get distributions and fund recycling moving

3

Exit size, not count, is the new signature -- a few giants dominate the tally

4

Trillion-dollar AI IPOs ahead could dwarf even this quarter's record deals

TC
The VC Read ยท Trace's TakeTrace Cohen

The exit drought is officially over -- but read the fine print. This is a top-heavy recovery: SpaceX, Cursor, Cerebras and a handful of giants are driving the totals while the median startup's path to liquidity is still narrow. That matters for LPs celebrating 'distributions are back' -- the distributions are concentrated. The real fireworks are still loaded: OpenAI and Anthropic filing to test the trillion-dollar mark would dwarf everything here. The one cloud is the SCOTUS agency ruling -- a more politically directed SEC is a new variable in a pipeline that finally got moving.

๐Ÿ“ˆ 2026 IPO Tracker โ†’๐Ÿ’ฐ Funding Tracker โ†’

The second quarter of 2026 saw the most billion-dollar startup exits since 2021, according to Crunchbase data, a clear marker that the venture liquidity window has reopened after a multi-year freeze. The standout was SpaceX's long-awaited IPO, which debuted at a roughly $2.1 trillion first-day market capitalization and raised approximately $75 billion -- and the company's subsequent $60 billion acquisition of Cursor parent Anysphere, described as the priciest purchase of a private, venture-backed startup ever.

The quarter's defining feature was size rather than volume. Crunchbase notes that exit counts still sit well behind the 2021 high, when the IPO and SPAC boom flooded the market -- but the magnitude of individual deals is in a different league. Alongside SpaceX, Cerebras Systems went public in May raising at least $5.55 billion and holding a roughly $38 billion market cap, and quantum-computing firm Quantinuum raised $1.7 billion at an initial $15.6 billion valuation.

The context is years of pent-up demand. After 2022's downturn shut the IPO window and slowed M&A to a crawl, late-stage startups piled up at record valuations with no path to liquidity, leaving LPs starved of distributions and venture funds unable to recycle capital. A quarter this rich in billion-dollar outcomes begins to unclog that pipe, and the secondary and follow-on activity that trails mega-exits compounds the effect across the ecosystem.

โ€œThe Rocket Lab-Iridium deal and a broader wave of strategic M&A suggest acquirers, newly liquid from their own IPOs, are deploying stock to consolidate.โ€

The bigger acts may be ahead. Both Anthropic and OpenAI have filed confidentially for IPOs that, as Crunchbase puts it, could test the trillion-dollar mark -- listings that would dwarf even SpaceX's debut and complete the transition of the AI era's defining companies into public hands. The Rocket Lab-Iridium deal and a broader wave of strategic M&A suggest acquirers, newly liquid from their own IPOs, are deploying stock to consolidate.

For GPs and LPs, the read is cautiously optimistic: the exit machine is running again, but it is top-heavy, with a handful of giants driving the totals. That concentration means the median startup's path to liquidity may still be narrow even as the headline figures soar.

The bear case is that a tally inflated by a few enormous outliers can mask thinner activity beneath, and that any wobble in public markets -- or a more politically directed SEC after the Supreme Court's agency ruling -- could chill the pipeline. What to watch: whether OpenAI and Anthropic price their IPOs in 2026, whether exit volume broadens beyond the megadeals, and how the newly public AI and space winners deploy their currency.

ShareXLinkedInEmail
More onSpaceX โ†’Cursor โ†’Anthropic โ†’OpenAI โ†’

Originally reported by Crunchbase News. Analysis and editorial commentary by Value Add Pulse.

โ† Back to Pulse

Markets Now

live
S&P 500โ–ฒ+1.04%
7,433.98
NASDAQโ–ฒ+1.61%
25,766.42
NVDAโ–ผ-0.89%
$194.00
MSFTโ–ฒ+4.49%
$368.67
AAPLโ–ฒ+2.55%
$282.18
GOOGLโ–ฒ+2.69%
$352.95
METAโ–ฒ+4.19%
$565.64
AMZNโ–ฒ+5.87%
$240.34

Read Next

IPO

OpenAI and Anthropic File Confidential S-1s, Racing to Public Markets

OpenAI and Anthropic have both confidentially filed S-1s, with OpenAI targeting a Q4 2026 listing as Anthropic -- fresh off a ~$65B round lifting its valuation toward $965B -- races it to public markets. When both labs trade, every MANGOS member will be in public hands.

IPOS-1 filed

Classover Rebrands as KIDZ AI and Files S-1 to Fund AI Learning and Compute Push

KIDZ AI Inc. (Nasdaq: KIDZ), the AI-education company formerly known as Classover Holdings, filed a Form S-1 with the SEC as it pivots from live online enrichment classes for kids toward AI-powered learning systems -- and, notably, AI compute infrastructure and GPU cloud. The rebrand-and-refile captures both the edtech-AI wave and the 2026 trend of small caps chasing the AI-infrastructure story.

IPOS-1 filed

Jupiter Neurosciences Files S-1 to Fund Its Neuroinflammation and Longevity Pipeline

Clinical-stage biotech Jupiter Neurosciences (Nasdaq: JUNS) filed a Form S-1 with the SEC to register fresh capital as it advances its lead candidate JOTROL, a proprietary resveratrol platform targeting rare and neuroinflammatory CNS disorders and, increasingly, longevity. The filing adds another central-nervous-system name to a 2026 biotech pipeline that keeps widening alongside AI and chips.

@Trace_Cohenยทt@nyvp.com